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Calcification (CALC) of bioprosthetic heart valves (BHVs) fabricated from either glutaraldehyde-pretreated bovine pericardial 
tissue or porcine aortic valves is the most frequent cause of clinical failure of these devices. Previous studies have demonstrated that 
calcification is inhibited by diphosphonate compounds released into the vicinity of bioprosthetic tissue implanted subcutaneously in 
rats. Controlled release of the anticalcification agent ethanehydroxy diphosphonate (EHDP), as a 1:l mixture of Na,EHDP and 
CaEHDP from cylindrical polyurethane (PU) reservoirs (o.d. = 0.36 cm, id. = 0.33 cm, length = 4 cm) fabricated by solvent casting 
was assessed in vitro and in viva. The diffusivity (D), determined independently using standard diffusion cells, for ionic EHDP 
diffusion across the PU membrane was 1.2 X 10mio cm’/s. Volume influx of buffer into the reservoirs in vitro was observed 
experimentally to reach a maximum at 7.8 days (288 + 44 ~1) with a biexponential decline to 147 f 6 ~1 at 70 days. The cumulative 
EHDP released in vitro after 70 days was 4.2 + 0.6% (4.8 k 0.7 mg) compared to 15.7 i 3.2% (18.1 +_ 3.7 mg) in vivo (subcutaneously 
in 3 week-old, male, CD rats) over 21 days. The release rate of EHDP from the reservoirs was not a zero-order process. Reservoir 
administration of EHDP effectively inhibited pericardial BHV-CALC in 21-day subdermal explants (Ca*+ = 4.5 + 1.4 ng Ca’ +/mg 
tissue; control, Ca*+ = 120 + 13 pg Ca*+/mg tissue) without diphosphonate-related untoward effects at a dose of approx. 3 mg/kg _
per day. 
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Introduction 
Pathologic calcification is the primary process 
leading to sterile degeneration of bioprosthetic 
heart valves (Milan0 et al., 1984; Schoen and 
Levy, 1984; Schoen and Hobson, 1985; Schoen, 
1987) fabricated from either glutaraldehyde-pre- 
treated porcine aortic valves or bovine peri- 
cardium. Dysfunction of the calcified biopros- 
thetic heart valve typically results from either 
stenosis or secondary calcific tearing of the leaf- 
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lets. Pathologic deposition of calcium phosphate 
crystals is also important in other cardiovascular 
diseases such as arteriosclerosis (Levy et al.. 1983a). 
myocardial infarction (Hagler et al.. 1981) valvu- 
lar heart disease (Levy et al., 1980), and minerali- 
zation of the elastomeric blood-contacting surfaces 
of artificial heart devices (Pierce et al., 1980). 
Despite the prevalence of cardiovascular calcifica- 
tion, the pathophysiology of BHV calcification is 
incompletely understood (Schoen et al., 1985a, 
1988). Recently, much research has been directed 
at developing satisfactory means for its preven- 
tion. 
The calcification of bioprosthetic heart valves 
has been extensively investigated experimentally. 
Animal models utilized in studying BHV-CALC 
have involved orthotopic valve replacements or 
conduit-mounted valves in sheep and calves 
(Barnhart et al., 1982a; Levy et al., 1983b; 
Thubrikar et al., 1983: Gallo et al.. 1987). and 
subcutaneous implants in mice (Levy et al.. 1983~). 
rats (Levy et al., 1983d.e). and rabbits (Fishbein et 
al., 1982). Many of the pathologic findings from 
long-term clinical implants are simulated by the 
subcutaneous and circulatory animal models 
(Fishbein et al., 1982; Levy et al.. 1983c,d: Barn- 
hart et al., 1982b; Arbustini et al., 1984; Schoen et 
al., 1985b). 
Ethanehydroxy diphosphonate (EHDP) has 
been shown to inhibit effectively experimental 
BHV calcification (Levy et al.. 1985b,c). However. 
subcutaneous administration of EHDP to rats at 
doses greater than 15 mg/kg per day has been 
shown to be associated with adverse effects on 
overall somatic growth. bone development. and 
serum Ca’ + levels (Levy et al., 1987). Neverthe- 
less, controlled release of EHDP from a variety of 
polymeric matrices directly into BHV tissue pre- 
vented BHV-CALC using minimal local doses and 
avoided adverse effects (Levy et al.. 1985b,c: 
Golomb et al., 1986a,b. 1987). 
The purpose of the present study was to fabri- 
cate controlled release polyurethane reservoirs and 
evaluate their in vitro release profiles and in vivo 
efficacy and function using the rat subdermal 
model of bioprosthetic tissue calcification. Ad- 
ditional experiments assessed the fluid dynamics 
during in vitro release and the diffusion coeffi- 
cient for EHDP through the polyurethane mem- 
brane used in our reservoirs. The advantage of the 
present drug delivery device compared to EHDP- 
polymer matrices is the potential for constant 
(zero-order) delivery of EHDP and replenishment 
of EHDP following drug exhaustion. 
Experimental 
Materials 
Mitrathane (MPU-5). a medical grade poly- 
ether-urea-urethane, was provided by Matrix 
Medica (Wheatridge, CO) as a 25% w/v solution 
in dimethylacetamide and as solvent-cast sheeting 
having a thickness of 150 k 6 pm. Disodium 
ethanehydroxy diphosphonate (Na L EHDP) was 
provided by Norwich Eaton (Norwich. NY). 
Na,[ “C]EHDP (specific activity: 48.9 ~Ci/mmol) 
and the calcium salt of EHDP were provided by 
Proctor and Gamble (Cincinnati. OH). NaJ 14C] 
EHDP was diluted with unlabelled Na,EHDP to 
yield a specific activity of 3800 dpm/pmol. The 
diluted Naz[ 14C]EHDP was then mixed in a 1:l 
ratio with CaEHDP and the resulting mixture 
sieved to obtain a uniform particle size of 90-106 
pm. Atomlight scintillation solution was obtained 
from New England Nuclear (Billerica, MA). 
Parietal pericardium was obtained fresh at 
slaughter from steers and immediately placed in 
iced sterile saline for not longer than 1 h. Superfi- 
cial fat was dissected from the external surfaces 
and the pericardium then transferred to 0.8q, 
glutaraldehyde (E.M. grade, Polyscience. Warring- 
ton. PA) in a physiologic buffer (0.05 M Hepes in 
0.1 M NaCl, pH 7.4) for a 2-week period to 
initiate cross-linking. The glutaraldehyde buffet 
containing the pericardium was stored at 4” C. 
Methods 
Polyurethane membranes and reservoirs 
The medical grade polyurethane sheeting was 
used as received in the diffusion study after cut- 
ting 1 x 1 inch membranes to mount in each diffu- 
sion cell. Polyurethane reservoirs were fabricated 
by dipping teflon-coated steel rods (o.d. = 0.33 
cm) into the polyurethane solution. Excess liquid 
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polyurethane was removed and the rods sus- 
pended vertically to allow the organic solvent to 
volatilize. After air drying for 2 days, the re- 
servoirs were removed from the teflon rods, one 
end of the reservoir was sealed with cyanoacrylate 
ester (Super Glue, Locktite, Cleveland, OH), the 
reservoir filled with the presieved, powdered 
Na,[‘4C]EHDP/CaEHDP mixture, and the sec- 
ond end sealed. Reservoirs fabricated by this pro- 
cedure had a length of 4 cm and a wall thickness 
of 150 k 17 pm (i.d. = 0.36 cm, i.d. = 0.33 cm). 
The resulting PU reservoirs contained an average 
of 229 k 3 mg of the 1:l Na,[i4C]EHDP/ 
CaEHDP mixture. 
In vitro release of Na,[‘4C]EHDP 
Preloaded reservoirs containing Na 2[ 14C]- 
EHDP/CaEHDP (1:l) were incubated at 37°C 
in 24 ml of a physiologic buffer (0.05 M Hepes 
adjusted to 0.15 M with NaCl, pH 7.4) with con- 
stant stirring (150 rpm) by using an orbital shaker 
(Lab Line, Melrose Park, CA). At specified time 
points over the 70 day in vitro release period, 
reservoirs were removed from the buffer, gently 
washed with distilled water to remove any radio- 
active drug solution adhering to the surface of the 
reservoir, and then placed in 24 ml of fresh buffer. 
A 5 ml aliquot of the receptor phase containing 
solubilized Na,[‘4C]EHDP was removed, com- 
bined with 15 ml of the scintillation fluor and then 
counted for 14C activity on a Beckman liquid 
scintillation counter (model no. 3801, Berkeley, 
CA). The release profiles of Na,[‘4C]EHDP from 
the controlled release PU reservoirs were ex- 
pressed as the cumulative % Na,[‘4C]EHDP re- 
leased vs time. 
Diffusion studies 
The value of D for [14C]EHDP diffusion across 
a 150 pm thick PU film was determined using 
standard diffusion cells at 37” C with constant 
stirring. The receptor solution was a physiologic 
buffer (see above) preserved with 0.5% sodium 
azide. Periodically, samples of the receptor phase 
were removed, counted for 14C activity in a liquid 
scintillation counter and the % EHDP diffused 
calculated as a function of time. 
Reservoir volume influx studies 
Identical drug-loaded reservoirs (see above) 
were also assessed in vitro for volume influx of 
buffer during the 70 day release period. Reservoirs 
were removed from the buffer at regular intervals 
and the exterior surface blotted dry of surface 
adhering buffer. The reservoirs were then weighed 
on an analytical balance and the resulting weights 
compared to the initial preincubation weight of 
the drug-loaded reservoir to calculate the amount 
(volume) of buffer imbibed. 
Rat subdermul studies 
Prior to implantation, 10 reservoirs were al- 
lowed to release EHDP into a physiologic buffer 
(see above) for 6 days (approx. 2 X t,,,) to ensure 
that release of EHDP from the reservoirs was 
proceeding at a constant rate (zero-order) based 
on preliminary results of the EHDP diffusion 
studies. Ten rats (3-week-old, male CD strain, 
Charles River Labs, Wilmington, MA) were im- 
planted subcutaneously with drug-loaded re- 
servoirs on the dorsal side adjacent to a 3.0 x 0.9 
cm2 strip of glutaraldehyde-pretreated, bovine 
pericardial tissue. An additional 7 rats were im- 
planted as above with BHV tissue adjacent to 
empty PU reservoirs. Reservoirs and BHV tissue 
were explanted at 21 days. A representative sec- 
tion of the BHV tissue was immediately fixed in a 
cacodylate-buffered 2.5% glutaraldehyde-2% para- 
formaldehyde solution buffered at pH 7.2 (Kar- 
novsky, 1965) for 24 h and then dehydrated in 
graded ethanol solutions (Levy et al., 1985b) prior 
to embedding in glycolmethylmethacrylate (JB-4, 
Polysciences, Warrington, PA). Sections (2-3 pm) 
were stained with hematoxylin and eosin for over- 
all morphologic analyses and Von Kossa’s reagent 
for calcium phosphate (Levy et al., 1985b). The 
remaining portion of each piece of BHV tissue 
was prepared for quantitative analysis of calcium 
using atomic absorption spectroscopy (Levy et al., 
1980, 1983d). 
Explanted reservoirs were dried at 100°C for 
12 h, opened, and the luminal contents removed 
as a dry pellet. Each cylindrical, rod-shaped pellet 
was dissolved in 20 ml of deionized water, the 
solution sonicated (Branson sonifier, model 250, 
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Shelton, CN) and then sampled (5 ml) to de- 
termine 14C activity. 
All data were expressed as the mean -+ standard 
error of the mean (SE). The in vitro release and 
the diffusion studies expressed the mean cumula- 
tive percentage of [t4C]EHDP released or dif- 
fused, respectively. Comparisons of means were 
performed using the Student’s t-test. Polyexponen- 
tial equations used to predict the time course for 
buffer influx into the reservoirs, amount of drug 
released from the reservoirs, and decrease in the 
value of the permeability (DK) of MPU-5 to 
[‘“C]EHDP were determined according to a non- 
linear least-squares regression routine (Bolt et al., 
1984). Initial parameter estimates for the nonlin- 
ear fitting routine were obtained graphically via 
the method-of-residuals. 
Results and Discussion 
The present study has successfully demon- 
strated the fabrication and characterization of 
EHDP controlled release reservoirs. EHDP de- 
livery was characterized in vitro and in vivo and 
the efficacy of this novel reservoir system was 
demonstrated in a rat subdermal calcification 
model. 
The value of D was calculated with Eqn. 1: 
D = 12/6 ’ tlag (1) 
where fiag denotes the lag-time (s) and I is the 
polymer membrane thickness (cm). Eqn. 1 as- 
sumes that a steady state has been achieved for a 
constant-activity reservoir device (Fig. 1) (Baker, 
1987). The lag-time (3.58 days) for EHDP diffu- 
sion through the MPU-5 membrane (0.015 cm) 
was experimentally determined by back extrapola- 
tion to the x-axis of the steady-state portion of the 
curve illustrated in Fig. 1. Thus, the value of the 
apparent D was determined to be 1.2 X lo-“’ 
cm2/s. 
Fig. I. Diffusion of Na+HDP through wlwnt-cast Mitrathant! 
(MPU-5) membrane. (W) Mean :i_ S.F.. 
Rapid influx of physiologic buffer into the re- 
servoir lumen was observed as early as 23 h after 
the initiation of in vitro release of [‘4C]EHDP 
(Fig. 2). Following 23 h of in vitro release, approx. 
170 & 10 ~1 of physiologic buffer (approx. l/2 the 
reservoir’s calculated internal volume) had been 
imbibed. Continual uptake of fluid to 7.8 days 
was observed experimentally, whereupon the 
volume of fluid inside the reservoir began to de- 
crease in a biexponential fashion for the duration 
of the in vitro release period. The internal volume 
of the reservoir as a function of time was esti- 
mated as the sum of the internal volume of the 
empty reservoir and the volume of buffer imbibed 
in excess (net buffer imbibed, Fig. 2) of the volume 
required for dissolution of the Na:EHDP and 
Fig. 2. Reservoir volume Influx vs in vitro incubation time in 
physiologic buffer. (m) Mean + SE; ( - ) nonlmear regres- 
sion (Bolt et al.. 1984) fit of the data. 
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TABLE 1 
Controlled releuse reservoir transport parameters: macroconstants associated wrth polyexponentml eyuutions 
Parameter (I) Pre-exponential coefficient 
A B c 





V(f) ‘+ 3 546 149 - 3 703 0.136 2.54 x 1O-5 0.153 
Permeability, 
P(f) 4.93 x10-” 4.18 x lo-” _ 0.479 0.0462 
Diffusion 
coefficient, D( f ) 9.30 x lo-” 7.88 x lo’-” 0.479 0.0462 
d v(t) zAexp’+” + Bexp(-‘2’) + Cexp’-X”‘, 
which was required to fill the void volume 
(30-40%) between the CaEHDP salt particles fol- 
lowing Na,EHDP dissolution. The volume of the 
buffer imbibed in excess of the volume needed to 
facilitate dissolution of Na,EHDP and to fill the 
void volume between the poorly soluble CaEHDP 
particles following Na,EHDP dissolution was 
calculated by using a triexponential equation (Ta- 
ble 1) and is shown in Fig. 2. If it is assumed that 
bulk flow of buffer into the cylindrical reservoir 
caused the reservoir to expand in a uniform, cylin- 
drical manner, then it should be possible to 
quantitate the surface area (A) of the reservoir as 
a function of time knowing only the time-depen- 
dent internal volume of the reservoir. Theoreti- 
cally, the surface area of the reservoir available for 
drug transport should reach a maximum at the 
same time the volume of buffer imbibed described 
by the t~exponential fit reaches a maximum, i.e., 
at 8.8 days. 
In vitro release of [‘4C]EHDP 
The percent of [r4C]EHDP delivered in vitro 
can be noted in Fig. 3 and Table 2. As a result of 
the rapid and extensive influx of buffer into the 
reservoirs at early time points, the continual loss 
of drug to the bulk receptor phase, and dilution of 
remaining drug by imbibed buffer, the internal 
drug concentration decreased with time. Thus, 
first-order release behavior for ]‘4C]EHDP was 
observed (Fig. 3) and a classical analysis for a 
cylindrical reservoir having an internal drug solu- 
tion of nonconstant thermodynamic activity was 
employed through use of Eqn. 2 (Baker, 1987): 
M( t ) = Mm [f - exp(-““K’Vi)t] (2) 
where M(t) and M, denote the amount of 
[14C]EHDP released at time t and initially con- 
tained in the reservoir, respectively, t is time (s), 
A is the surface area of the reservoir (cm2), D is 
the diffusion coefficient of [‘4C]EHDP (cm’/s), K 
is the partition coefficient (C,,,,,/C,,,,,), I is the 
membrane thickness (cm), and V is the internal 
volume of the reservoir (cm3). Eqn. 2 assumed 
that A, D, K, V, and I are constant. However, 
TABLE 2 
fnhthrtron of hioprosthetic heart uualve calcification in rats using reservoir-based administration of EHDP (?l-dyv implants) 
Group N Tissue Ca*+ EHDP released 
t pLg/mg) in vivo 
(W) 
Unimplanted 7 3.0 f 0.5 _ 
Control 10 120 +13 _ 
Empty reservoir 7 107 *14 
Reservoir 10 4.5 i 1.4 15.7 + 3.2 












none of these variables are constant under the 
experimental conditions. Upon separation of the 
variables in Eqn. 2, followed by the natural loga- 
rithm and finally, the derivative of both sides of 
the expression. one obtains Eqn. 3: 
dM(f) 
M, - M(r) 
= A(t)D(t)K(t) d* 
V(t)/(f) 
(3) 
Recognizing, from geometrical considerations. that 
A/V’ in Eqn. 3 is equal to 4/dia,,, and defining 
P(r) = D( t)K(t), the left-hand-side of Eqn. 3 can 
be set equal to {[4P(t)]/[dia,,,(t)l(t)]}dt. Solving 
the resulting expression for P(t) yields Eqn. 4 
where I(t) is assumed to be constant (0.015 cm) 
throughout the in vitro release period. 
The slope d[ M( t)/M,]/dt was determined from 
the release data shown in Fig. 3 at each time 
point. The time-dependent diameter of the re- 
servoir was calculated from the dimensional 
changes based on the internal volume of the empty 
reservoir and the volume of buffer imbibed (Table 
1) assuming the reservoir expanded in a uniform, 
cylindrical manner. Thus, the time-dependent per- 
meability, P(r), of the polyurethane test mem- 
brane to EHDP was calculated by using Eq. 4. 
The calculated values of the mean permeability 
of the solvent-cast polyurethane reservoirs to 
EHDP using Eqn. 4 are shown in Fig. 4. The value 
of the permeability decreases throughout the 70- 
day in vitro release period and may be described 
by a biexponential equation with preexponential 
coefficients and characteristic time constants 
shown in Table 1. 
Since the partition coefficient. K = [ “‘CIEHD- 
P mcnr,+’ ] ” WHDP,,,,, . was independently de- 
termined by the solution depletion method 
(Zentner et al., 1978a) to have a value of 0.53 ir 
0.04, the value of the diffusion coefficient, II. for 
[‘4C]EHDP transport across MPU-5 was calcu- 
lated ( D = DK/K ) as a function of time assuming 
that K was constant throughout the 70-day in 
vitro release period. However, it should be noted 
that the value of D calculated as such is only an 
estimate of the true diffusivity due to a potentially 
time-dependent value of K. As expected with divi- 
sion by a constant. the value of D plotted against 
time yields the same overall time-dependent pro- 
file as the value of P with preexponential coeffi- 
cients and characteristic time constants listed in 
Table 1. 
Previous research (Lyman, 1964: Lyman and 
Kim, 1973a,b) has shown that solutes permeate 
polyether urethanes by a solution-diffusion or par- 
tition mechanism. This type of solute permeation 
is characterized by dissolution of the soiute in the 
membrane followed by diffusion along and be- 
tween the polymer segments that make up the 
membrane structure (Zentner et al., 197Xb). The 
Fig. 4. C‘alculated values (A) of the mean (11 = 5) permeah!llt\ 
(P = DK) of solvent-cast (Mitrathane reservwrs to Na2EHDP. 
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physical-chemical properties of the solute and the 
polyether urethane membrane play a major role in 
determining the membrane permeabiIity with the 
solution-diffusion model (Zentner, 1978b). Inter- 
actions between the solute and the polymer seg- 
ments of the membranes can greatly influence the 
value of the diffusion coefficient (Zentner, 1978b). 
The time-dependent nature of P in the present 
study would suggest that initially, buffer was im- 
bibed with a concomitant rise in the osmotic-in- 
duced internal pressure. During the rapid re- 
servoir swelling phase (first 7 days), the high 
osmotic-induced pressure inside the reservoirs ap- 
peared to cause a ‘burst-effect’ of EHDP through 
the reservoir membrane. Thereafter, the ionic 
strengths of both solutions (internal drug solution 
and external receptor phase) potentially ap- 
proached an equilibrium value. This may account 
for the subsequent reduction in the mean value of 
the calculated permeability. EHDP may also form 
insoluble precipitates with components of the 
HEPES buffer or with polyurethane impurities. 
Assuming drug precipitation occurs in the lumen 
of the reservoir following approx. 7 days of in 
vitro release, the reservoir volume would then 
decrease to compensate for the loss of ions. 
Changes in osmotic pressure and drug con- 
centration in the lumen of the reservoir would 
appear to play an important role in affecting the 
value of D, and hence, P. Changes in the internal 
volume, osmotic pressure, drug concentration, and 
membrane thickness could all affect the value of 
D, since it is well documented that concentration, 
pressure, temperature, solvent properties, and the 
chemical nature of the diffusant may all affect the 
value of D (Martin et al., 1983; Cussler, 1984; 
Flynn et al., 1974). 
In vivo efficacy of EHDP delivered by reservoirs 
Reservoirs allowed to release [14C]EHDP in 
vitro for 6 days prior to implantation into rats 
delivered 2.9 ) 0.4% (3.3 f 0.5 mg) of EHDP. The 
EHDP released in vivo over 21 days was 15.7 i 
3.2% (18.1 & 3.7 mg). However, the greater release 
of EHDP in vivo (15.7 f 3.2%) as compared to in 
vitro after 70 days (4.2 + 0.6%) was possibly due 
to movement induced flexing and bending of the 
reservoir in the rat subdermal model coupled with 
possible hydrolytic degradation and subsequent 
microscopic cracking of the polyurethane mem- 
brane (Smith et al., 1987). Constant bending and 
flexing of the reservoirs in vivo may have caused 
slight leakage of the saturated Na,EHDP solution 
from the sealed ends of the device. 
EHDP administered by daily subcutaneous in- 
jections to rats is known to be associated with 
disturbed bone growth and altered serum calcium 
levels at doses exceeding 15 mg/kg per day (Levy 
et al., 1987). In the present study, complete inhibi- 
tion of BHV-CALC (Table 2) was observed at an 
overall dosage of 3.0 mg/kg per day by local, 
reservoir-based administration of EHDP. Morph@ 
logical exa~nation revealed that pericardial tissue 
implanted without reservoirs and that implanted 
adjacent to empty reservoirs had diffuse minerali- 
zation with a morphology similar to that noted in 
previous studies (Golomb et al., 1986a; Johnston 
et al., 1988). In contrast, tissue adjacent to 
EHDP-filled reservoirs had only minimal, focal 
calcific deposits, considerably diminished relative 
to control implants. Inhibition of BHV-CALC 
using this local controlled drug delivery approach 
was not associated with untoward effects on 
growth, bone development, or serum Ca2+ levels. 
Implications 
The present polyurethane drug delivery system 
has important implications for the prevention of 
bioprosthetic heart valve calcification. Reservoirs 
fabricated using RMitrathane appeared to possess 
satisfactory mechanical strength despite stretching 
of the membrane in response to solvent influx. 
Both mechanical strength and biocompatibility 
would be a prerequisite for controlled drug de- 
livery in the circulation where such a device would 
encounter different hydrodynamic conditions and 
pressure gradients. 
By limiting the area available for solvent influx, 
the present reservoir system has the potential for 
zero-order release of EHDP. The polyurethane 
reservoirs might be engineered in such a way as to 
connect the lumen of the reservoir to a water-im- 
permeable, biocompatible cannula that would lead 
to a percutaneous access device (PAD) situated 
subcutaneously. The reservoir could be refilled 
following drug exhaustion by a standand needle 
injection of a saturated solution of EHDP into a 
conveniently located PAD which had previously 
been implanted subcutaneously. 
A refillable reservoir system might also enhance 
therapeutic efficacy when used in combination 
with EHDP containing matrices or osmotically 
driven pump systems. In addition. the possibility 
of further enhancing therapeutic benefit by com- 
bining EHDP drug delivery devices (refillable re- 
servoirs. matrices, osmotic pumps. etc.) with BHV 
tissue pretreatment strategies also exists. The com- 
bination of treatment strategies would assure both 
short- and long-term release of EHDP to inhibit 
BHV CALC. 
Refillable reservoir systems could be used for 
treating other cardiovascular diseases. A variety of 
cardiovascular drugs could be delivered at a con- 
stant rate by using this system. Those compounds 
less water-soluble than EHDP would be expected 
to permeate the reservoir membrane more slowly. 
result in less solvent/plasma uptake. and thereby. 
result in a more protracted zero-order release pro- 
file. 
Conclusions 
Based on the results of the present study. 
n Mitrathane or other comparable medical-grade 
polyurethanes might be suitable rate-limiting 
membranes for use in a reservoir device contain- 
ing Na-CaEHDP. Further sustained release of 
EHDP is possible by exploiting the low aqueous 
solubility of CaEHDP (Nash, 1984; Golomb et al.. 
19X7). Additional strategies to modify EHDP re- 
lease rate would be varying either the total surface 
area available for solvent influx or the hy- 
drophilicity (ratio of polyethylene glycol/urethane 
segments) of the copolymer. 
Interaction of the EHDP anion with the poly- 
mer membrane used in the present study may 
contribute to a time-dependent diffusion coeffi- 
cient for EHDP transport. Changes in the internal 
osmotic pressure, drug concentration. and mem- 
brane thickness as well as EHDP potentially for- 
ming insoluble precipitates with components of 
the Hepes buffer were additional variables sug- 
gested to contribute to the time-dependent value 
of the diffusion coefficient. Further studies are 
required to determine if alterations in the permea- 
bility of RMitrathane to EHDP anion result from 
binding of the charged drug molecule to sites 
contained in the polyurethane and whether EHDP 
forms insoluble precipitates with components in 
Hepes buffer and/or impurities in the polv- 
urethane membrane. 
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